GIG CYMRU NHS WALES | Bwrdd Iechyd Prifysgol Caerdydd a'r Fro | Cardiff and Vale University Health Board

Freedom of Information Act 2000 – Request Reference FoI/24/290
Biologic Products

We are analysing the usage of biologic and biosimilar products within Rheumatology and it would be really helpful if you could please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

The below figures represent the number of patients issued with the listed drugs by the Rheumatology Department from 1 February 2024 to 30 April 2024.

- Abatacept [Orencia] – 49
- Adalimumab [Humira] – 32
- Adalimumab Biosimilars – 281
- Apremilast [Otezla] – 2
- Baricitinib [Olumiant] – 41
- Bimekizumab [Bimzelx] – 0
- Certolizumab [Cimzia] – 85
- Etanercept [Enbrel] – 22
- Etanercept Biosimilars – 188
- Filgotinib [Jyseleca] – 1
- Golimumab [Simponi] – 36
- Guselkumab [Tremfya] – 3
- Infliximab [Remicade] – 3
- Infliximab Biosimilars – 19
- Ixekizumab [Taltz] – 7
- Risankizumab [Skyrizi] – 0
- Rituximab [MabThera] – 2
- Rituximab Biosimilars – 45
- Sarilumab [Kevzara] – 9
- Secukinumab [Cosentyx] – 30
- Tocilizumab [Ro Actemra] – 98
- Tocilizumab Biosimilars – 0
- Tofacitinib [Xeljanz] – 8
- Upadacitinib [Rinvoq] – 19
- Ustekinumab [Stelara] – 16